Gastroesophageal junction (Siewert III) adenocarcinoma
Showing 1 - 25 of >10,000
Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- toripalimab FOLFOX
- (no location specified)
Aug 3, 2023
Novel Staging Schemes for Siewert Type II Esophagogastric
Completed
- Adenocarcinoma of the Esophagogastric Junction
- esophagogastric junction cancer surgery
-
Fuzhou, Fujian, ChinaFujian Medical University Union Hospital
Nov 1, 2022
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)
Not yet recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Cadonilimab
- +5 more
- (no location specified)
Jul 17, 2023
Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)
Recruiting
- Gastroesophageal Junction Adenocarcinoma
-
Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2023
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical
Not yet recruiting
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- +5 more
- Biospecimen Collection
- +9 more
-
Scottsdale, Arizona
- +2 more
Oct 11, 2023
Siewert Type II Adenocarcinoma of Esophagogastric Junction Trial in Xi'an (Endoscopy Ivor-lewis, Laparoscopic transabdominal
Recruiting
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Endoscopy Ivor-lewis
- Laparoscopic transabdominal enlarged gastrectomy
-
Xi'an, Shaanxi, ChinaLi
Jun 7, 2022
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial
Not yet recruiting
- Advanced Esophageal Adenocarcinoma
- +14 more
- Fluorouracil
- +8 more
- (no location specified)
Jan 3, 2023
Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)
Recruiting
- Gastric Cancer
- +10 more
- Docetaxel
- +3 more
-
Kyiv, UkraineNational Cancer Institute
Aug 31, 2023
Adenocarcinoma of Stomach Trial in Shanghai (Gentuximab Injection, Gentuximab Injection Placebo)
Recruiting
- Adenocarcinoma of Stomach
- Gentuximab Injection
- Gentuximab Injection Placebo
-
Shanghai, Shanghai, ChinaShanghai Dongfang Hospital
Jun 16, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)
Recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- PD-1 inhibitor
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Aug 9, 2023
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction Trial
Not yet recruiting
- Adenocarcinoma Esophagus
- +3 more
- Vactosertib
- +2 more
- (no location specified)
Sep 13, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab)
Completed
- Esophageal Carcinoma
- Esophagogastric Junction Carcinoma
- pembrolizumab
- (no location specified)
Aug 18, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Capecitabine
- +3 more
-
Beijing, Beijing, China
- +10 more
Nov 23, 2023
Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction Trial in Guangzhou (Docetaxel for injection (Albumin-bound),
Recruiting
- Gastric Adenocarcinoma
- Adenocarcinoma of Gastroesophageal Junction
- Docetaxel for injection (Albumin-bound)
- Taxotere
-
Guangzhou, ChinaEthics Committee of Sun-Yat-Sen University Cancer Center
Jan 27, 2023
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III
Recruiting
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- +10 more
- Biopsy
- +8 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 20, 2023
Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with
Enrolling by invitation
- Gastric / Gastroesophageal Junction Adenocarcinoma
- envafolimab and lenvatinib combined with paclitaxel-albumin
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Sep 3, 2023
Gastric Cancer Trial (S-1, Oxaliplatin, Cadonilimab)
Not yet recruiting
- Gastric Cancer
- S-1, Oxaliplatin, Cadonilimab
- (no location specified)
Jul 10, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (XELOX combined with Fruquintinib and Sintilimab)
Not yet recruiting
- Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- XELOX combined with Fruquintinib and Sintilimab
- (no location specified)
Oct 17, 2023
Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)
Recruiting
- Advanced Gastric Adenocarcinoma
-
Henan, ChinaHenan Tumor Hospital
Oct 13, 2022
Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)
Recruiting
- Gastric Cancer
- +3 more
- Fruquintinib + SOX
-
Nanning, ChinaGuangxi Medical University Cancer Hospital
Dec 2, 2022
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8,
Recruiting
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- +23 more
- Atezolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 5, 2022
Esophageal Adenocarcinoma Trial in Clermont-Ferrand (Adipose tissue biopsies)
Not yet recruiting
- Esophageal Adenocarcinoma
- Adipose tissue biopsies
-
Clermont-Ferrand, FranceCHU de Clermont-Ferrand
Jul 19, 2023
Esophageal Cancer Trial (Hypofractionated radiotherapy)
Not yet recruiting
- Esophageal Cancer
- Hypofractionated radiotherapy
- (no location specified)
Jan 18, 2023